Base-case cost-effectiveness analysis
| Base-case model . | PSA model . | |||||
|---|---|---|---|---|---|---|
| Strategy . | Cost, $ . | Incremental cost, $ . | Effectiveness (QALY) . | Incremental effectiveness (QALY) . | ICER ($/QALY) . | ICER 95% confidence interval ($/QALY) . |
| Third-line CAR T-cell therapy | 731 682 | 273 191 | 7.04 | 1.50 | 182 127 | 147 469-229 576 |
| Third-line SOC therapies | 458 490 | — | 5.54 | — | — | — |
| Base-case model . | PSA model . | |||||
|---|---|---|---|---|---|---|
| Strategy . | Cost, $ . | Incremental cost, $ . | Effectiveness (QALY) . | Incremental effectiveness (QALY) . | ICER ($/QALY) . | ICER 95% confidence interval ($/QALY) . |
| Third-line CAR T-cell therapy | 731 682 | 273 191 | 7.04 | 1.50 | 182 127 | 147 469-229 576 |
| Third-line SOC therapies | 458 490 | — | 5.54 | — | — | — |